ArticleJACC. Cardiovascular interventions2020
Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries.
Article in JACC. Cardiovascular interventions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Diagnostic Approach to Left Ventricular Hypertrophy: A Review.US cardiology · 2026Review
- Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure.Nature communications · 2025Article
- A new wearable e monitoring technology for evaluation of left ventricular remodeling after transcatheter aortic valve replacement.European heart journal. Digital health · 2025Article
- Impact of Left Ventricular Mass on Mortality in Symptomatic Severe Aortic Stenosis: A Sex-Specific Analysis.Life (Basel, Switzerland) · 2025Article
- Electrocardiography versus Echocardiography in Severe Aortic Stenosis with the Consideration of Coexistent Coronary Artery Disease.Journal of clinical medicine · 2024Article
- Review
- Metabolic Signatures of Cardiac Dysfunction, Multimorbidity, and Post-Transcatheter Aortic Valve Implantation Death.Journal of the American Heart Association · 2023Article
- Left ventricular mass regression after aortic valve replacement with the TTK Chitra™ monoleaflet tilting disc valve.Indian journal of thoracic and cardiovascular surgery · 2023Article
- Left ventricular hypertrophy as a predictor of cardiovascular outcomes after transcatheter aortic valve replacement.ESC heart failure · 2023Observational
- Interaction between sex and left ventricular reverse remodeling and its association with outcomes after transcatheter aortic valve implantation.The international journal of cardiovascular imaging · 2022Article
- Evaluation of Ventricular Remodeling and Prognosis in Patients with Aortic Stenosis Who Underwent Surgical or Percutaneous Transcatheter Aortic Valve Replacement.Brazilian journal of cardiovascular surgery · 2022Article
- Left Ventricular Hypertrophy and Biomarkers of Cardiac Damage and Stress in Aortic Stenosis.Journal of the American Heart Association · 2022Article
- Implication of Different ECG Left Ventricular Hypertrophy in Patients Undergoing Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2022Observational
- Assessment of left ventricular contractility in patients with severe aortic stenosis, low-flow, low-gradient and preserved ejection fractionArchivos de cardiologia de Mexico · 2022Article
- Long term mortality and readmissions after transcatheter aortic valve replacement.Cardiovascular diagnosis and therapy · 2021Article
- Challenges and opportunities in improving left ventricular remodelling and clinical outcome following surgical and trans-catheter aortic valve replacement.Frontiers of medicine · 2021Review
- Personalized intervention cardiology with transcatheter aortic valve replacement made possible with a non-invasive monitoring and diagnostic framework.Scientific reports · 2021Article
- Small Left Ventricle and Clinical Outcomes After Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2021Article
- The Early Bird Catches the Worm: Should Severe LVH Be an Indication for Early TAVR?JACC. Cardiovascular interventions · 2020Article
- Pre-dischargeIndian heart journalArticle
Corrections and comments
- Commented on by
Authors and funding
18 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study sought to evaluate the association between severity of left ventricular hypertrophy (LVH) before transcatheter aortic valve replacement (TAVR) and outcomes out to 5 years.
backgroundPrior studies assessing the association between baseline LVH and outcomes after surgical or TAVR for aortic stenosis (AS) have yielded conflicting results.
methodsPatients with severe symptomatic AS at intermediate or high risk in the PARTNER (Placement of Aortic Transcatheter Valve) 1, 2, and S3 trials and registries who received TAVR and had baseline measurements for left ventricular mass index (LVMi) were analyzed. The presence and severity of LVH was determined by LVMi using American Society of Echocardiography sex-specific cutoffs.
resultsAmong 4,280 patients, those with no (n = 1,325), mild (n = 777), moderate (n = 628), and severe (n = 1,550) LVH had 5-year rates of death of 32.8%, 37.3%, 37.2%, and 44.8%, respectively (p < 0.001), and 5-year rates of cardiovascular (CV) death or rehospitalization of 33.6%, 39.2%, 42.4%, and 49.2%, respectively (p < 0.001). After adjustment, severe LVH (compared with no LVH) was associated with increased all-cause death (adjusted hazard ratio: 1.16; 95% confidence interval: 1.00 to 1.34; p = 0.04) and CV death or rehospitalization (adjusted hazard ratio: 1.34; 95% confidence interval: 1.16 to 1.54; p < 0.001), but no increased hazard was observed for mild or moderate LVH. In spline analyses performed in males and females separately, there was a consistent linear association between increased LVMi and an increased adjusted hazard of CV mortality or rehospitalization. A similar relationship was observed for all-cause death in females, but not males.
conclusionsSevere baseline LVH is associated with higher 5-year death and rehospitalization rates after TAVR. These findings may have implications for the optimal timing of valve replacement and the potential role for medical therapy to slow or prevent LVH as AS progresses before valve replacement, but further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.